There are over 10,000 publicly listed biotechnology start-ups; while this figure seem large, it is dwarfed by the volume of tech start-ups floating through the markets. Like pharmaceuticals, these companies are trying to develop new medicines, but the basis of biotech medication is the use of live organisms for the synthesis of a medicine. This form of medication is cutting-edge and could lead to the next breakthrough in drug development.

While biotech firms are lead by ambitious teams and have managed to collectively raise billions of dollars each year, it could take many years for any of the drugs being developed to reach consumers.

Innovation is well-present in the drug industry and plenty of new medicines are being synthesized. However, this form of research requires extensive investment and even more money needs to enter the industry to pace the way the development of new drugs that will carry mankind into a reality where even more diseases have a valid cure.

A Very Long-Term Investment

It takes years for research to provide the data needed to create a drug. Once a drug is finally created, it takes an extensive amount of time for it to get the green light from government authorities.

Not only does drug research require an extensive amount of investment, it also forces investors to wait an incredible amount of time to enjoy the returns on their investment. These factors diminish the attractiveness of biotech capital raises as tech start-ups can potentially provide just as good returns but in a shorter time span. While technological advancements allow humanity to thrive, medical advancements allow humanity to survive.

Supporting Medical Advancements

A new blockchain project can provide the key to greater investment focus and innovative output in the drug industry.

ClinTex is developing an intelligence toolkit which is going to target the key pains that hold back the rise of more medical start-ups. The project creates a permissioned data hub of a network if pharmaceuticals that join its networks. While medicine start-ups may have limited funds to research operational and drug deployment efficiencies independently, they do have enough resources as a collective force.

ClinTex will allow these start-ups to share any data that can make it easier to speed up clinical trials; each will be able to share its own resourceful solutions.

Rather than have people analyze the data that could potentially be sourced from thousands of companies, ClinTex will provide applications that will analyze the data to provide clinical trial managers to get past their obstacles with ease.

Investors take into account opportunity cost and lowered trial timelines would lower the opportunity cost of investments given to medical start-ups. Lowered opportunity costs will make the net present value of investments in medicine start-ups more appealing and will give innovators in the field a competitive chance of raising funds.

Additionally, ClinTex provides tools that lower aggregate costs by providing efficiency via data-analyze solutions. Thus, not only are trial timelines reduced, the extra resources expensed when a trial is extended can now be saved.

This means that medicine start-ups can either successfully pursue developments with less capital or simply stretch the capital they have more than ever before.

ClinTex makes medicine start-ups a more appealing investment target by providing the value additive that can improve any business: efficiency.

With access to a shared data hub and the provision of data analysis applications, new industry players can improve their functionality and reduce their clinical trial costs; this in turn attracts more investors and allows the industry, that allows humanity to survive, to provide innovators with the funds they need to create life-saving drugs.